Health News

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2025 Earnings Snapshot through a link on...

LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co...

DUBLIN--(BUSINESS WIRE)--The "Protein Expression: Global Markets" has been added to ResearchAndMarkets.com's offering. The global protein expression market is poised for significant growth, with projections estimating an increase from $4.7 billion in 2025 to $7.9 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.9% during this period. The expansion of this market is fueled by substantial investments in biotechnology research and the escalating need for therapeutic proteins...

TORONTO--(BUSINESS WIRE)--dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL) announced today that the Company has received approval under the Investment Canada Act for its previously-announced plan of arrangement whereby a newly formed acquisition vehicle controlled by GTCR LLC (“GTCR”) will acquire all of Dentalcorp’s issued and outstanding subordinate voting shares and multiple voting shares (collectively, the “Shares”) (other than certain Shares owned by Graham Rosenberg, t...

ESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiestera...

BOSTON--(BUSINESS WIRE)--Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Richard A. Kresch, MD, to its Board of Directors. Dr. Kresch is a veteran healthcare executive and multi-time founder with more than 30 years of experience building, financing, and scaling provider businesses. He is Founder and Chief Executive Officer of US HealthVest, a network of behavioral health...

GOLDEN, Colo.--(BUSINESS WIRE)--Registrational Phase 3 study for advanced melanoma immunotherapy delivered with PharmaJet's IM Needle-free System planned for second half 2026....

WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to support the pre-IND development of KFRX06, KeifeRx’s preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson’s disease biology. Under the agreement, KeifeRx will conduc...

SAN FRANCISCO--(BUSINESS WIRE)--Combining Hippocratic AI’s safety-first technology and health care specialization with BCG’s strategic, operational, and AI transformation expertise...

PHILADELPHIA--(BUSINESS WIRE)--The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (“PxB Fund”), a dedicated venture capital fund focused on early-stage life science companies originating from Penn. The joint effort will provide additional fuel to advance Penn discoveries into products that benefit patients across the world, following a decade in which the u...